Genentech: Andy Stumpf | Senior Scientist, SMPC

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/andy-stumpf

Paste this link in an email to share.

Ok

Scientists / Our Scientists

Years at Genentech

Publications

I have always been fascinated by the power of synthetic organic chemistry and how it can best be applied to the development of new medicines in order to treat and cure human diseases. Over the last 20 years I have worked at both small and large organizations in the pharmaceutical industry, focusing to design efficient and environmentally friendly chemical processes that provide active pharmaceutical ingredients (API) for use in human clinical studies and beyond. Since joining Genentech in 2006 I have contributed to the supply of API’s for various new developmental medicines including the areas of cancer, immunology and antibody drug conjugates. I have very much enjoyed to be a part of Genentech’s multifaceted research and development organization that challenges and encourages deeper learning.

As a process chemist, I develop and optimize chemistry that is being employed in the synthesis of small molecule drug substances. With the goal in mind to eventually manufacture these compounds on commercial scale, I enjoy to put to practice the use of suitable technologies that enable process development, such as high throughput screening, calorimetric safety analysis and flow technology. Most of all I enjoy to simplify processes in order to make them more efficient.

I find it very rewarding to interact with various disciplines like Discovery Chemistry, QC, QA, Pharmaceutics, DMPK, Regulatory and Clinical Operations. Only as a team can we efficiently tackle the daunting task of developing a new medicine and bringing it to the patient.

Convergent Synthesis of PI3K Inhibitor GDC-0908 Featuring Palladium-Catalyzed Direct C-H Arylation toward Dihydrobenzothienooxepines

Journal of Organic Chemistry, ISSN: 00223263

Haiming Zhang; Beryl X. Li; Brian Wong; Andy Stumpf; C. Gregory Sowell; Francis Gosselin

Trace Analysis of Potentially Mutagenic Boronic Acids and Esters in Drug Substance by ICP-MS

Organic Process Research and Development, ISSN: 10836160

Ila Patel; C.J. Venkatramani; Andy Stumpf; Larry Wigman; Peter Yehl

The Discovery and Process Chemistry Development of GDC-0084, a Brain Penetrating Inhibitor of PI3K and mTOR

ACS Symposium Series, ISSN: 19475918

Tim Heffron; Andrew McClory; Andy Stumpf

View on Scopus

The Medicinal Chemistry and Commercial Manufacturing behind the Discovery and Development of the Hedgehog Inhibitor Vismodegib

ACS Symposium Series, ISSN: 19475918

Remy Angelaud; Dan Sutherlin; Mark Reynolds; Scott Savage; Andy Stumpf

View on Scopus

Development of an Expedient Process for the Multi-Kilogram Synthesis of Chk1 Inhibitor GDC-0425

Organic Process Research and Development, ISSN: 1520586X

Andy Stumpf; Zhigang Ken Cheng; Brian Wong; Mark Reynolds; Remy Angelaud; James Girotti; Alan Deese; Christine Gu; Lewis Gazzard

View on Scopus

A safe synthesis of 1,5-disubstituted 3-amino-1 H-1,2,4-triazoles from 1,3,4-oxadiazolium hexafluorophosphates

Synthesis (Germany), ISSN: 00397881

Brian Wong; Andy Stumpf; Diane Carrera; Christine Gu; Haiming Zhang

View on Scopus

Kilogram-scale asymmetric ruthenium-catalyzed hydrogenation of a tetrasubstituted fluoroenamide

Advanced Synthesis and Catalysis, ISSN: 16154150

Andy Stumpf; Mark Reynolds; Dan Sutherlin; Srinivasan Babu; Erhard Bappert; Felix Spindler; Michael Welch; John J. Gaudino

View on Scopus

University of Regensburg, Germany, Chemistry, Ph.D. – 1993
University of Marburg, Germany, Chemistry, B.S. – 1987

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

A link to this page has been copied to your clipboard.

Andy Stumpf

Senior Scientist, SMPC